Mesenteric ischemia surgery

Jump to navigation Jump to search

Mesenteric ischemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mesenteric ischemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Guidelines for Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRA

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mesenteric ischemia surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mesenteric ischemia surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mesenteric ischemia surgery

CDC on Mesenteric ischemia surgery

Mesenteric ischemia surgery in the news

Blogs on Mesenteric ischemia surgery

Directions to Hospitals Treating Mesenteric ischemia

Risk calculators and risk factors for Mesenteric ischemia surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Feham Tariq, MD [2]

Overview

Surgery in mesenteric ischemia is done to resect the ischemic bowel in order to prevent the complications. However, in case of acute embolic type of mesenteric ischemia, early laparotomy and surgical resection is the mainstay of treatment.

Surgery

  • The goals of surgical therapy are as follows:
    • Re-establishment of blood supply to the ischemic bowel
    • Resection of all non-viable areas of the bowel
    • Preservation of the viable bowel
  • Intestinal viability is defined as the maximum vital element influencing outcome in patients with AMI.
  • Non-viable bowel, if unrecognized, can cause multi-organ failure and lead to the death eventually.
  • Laparotomy allows to determine the viability of the bowel.
  • After preliminary resuscitation, midline laparotomy should be done to observe the areas of gut with choices for resection of all the necrotic areas. In instances of uncertainty, intraoperative Doppler can be beneficial.

Approach to treatment

The treatment modality chosen for the patient depends on the type and the location of occlusion, along with hemodyanamic stability.

Surgical versus endovascular intervention

  • In 2009, endovascular intervention was preferred over surgical approach.[1][2][3]

Endovascular intervention

  • Hemodyanamically stable patients and those who do not have clinical or radiological signs of ischemia are preferred candidates for endovascular intervention.[4][5][6]
  • Using endovascular intervention as the primary modality of treatment helps reduce complications, provides better outcome and shortens the length of hospital stay.[7]

Pharmacomechanical thrombolysis

Mesenteric angioplasty/stenting

Retrograde open mesenteric stenting

Abdominal exploration and damage control

Revascularization

  • Embolectomy:

The conventional treatment offered for mesenteric embolism is embolectomy. It clears the thrombus and helps assess the bowel viability.

  • Mesenteric bypass:

For mesenteric thrombosis, open surgical intervention is done followed by intraoperative retrograde superior mesenteric artery angiplasty and stenting for the atherosclerotic plaques.

Bowel and abdominal closure:

Postprocedural care and follow up:

Second-look lapratomy and abdominal wall closure:

Surgical procedure options:

[8][9][7]

  • Balloon catheter embolectomy of the superior mesenteric artery
  • For restoration of blood flow in acute mesenteric ischemia, antegrade aorto-mesenteric bypass from supraceliac aorta is the best choice.
  • Percutaneous transluminal angioplasty is also considered for revascularization in some case reports.
  • A new hybrid endovascular-surgical technique for managing mesenteric ischemia has been proposed.
  • Laprotomy is done when transmural bowel infacrction has occured.

References

  1. Arthurs ZM, Titus J, Bannazadeh M, Eagleton MJ, Srivastava S, Sarac TP; et al. (2011). "A comparison of endovascular revascularization with traditional therapy for the treatment of acute mesenteric ischemia". J Vasc Surg. 53 (3): 698–704, discussion 704-5. doi:10.1016/j.jvs.2010.09.049. PMID 21236616.
  2. Björnsson S, Resch T, Acosta S (2013). "Symptomatic mesenteric atherosclerotic disease-lessons learned from the diagnostic workup". J Gastrointest Surg. 17 (5): 973–80. doi:10.1007/s11605-013-2139-z. PMID 23307340.
  3. Sharafuddin MJ, Nicholson RM, Kresowik TF, Amin PB, Hoballah JJ, Sharp WJ (2012). "Endovascular recanalization of total occlusions of the mesenteric and celiac arteries". J Vasc Surg. 55 (6): 1674–81. doi:10.1016/j.jvs.2011.12.013. PMID 22516890.
  4. Ryer EJ, Kalra M, Oderich GS, Duncan AA, Gloviczki P, Cha S; et al. (2012). "Revascularization for acute mesenteric ischemia". J Vasc Surg. 55 (6): 1682–9. doi:10.1016/j.jvs.2011.12.017. PMID 22503176.
  5. Kougias P, Huynh TT, Lin PH (2009). "Clinical outcomes of mesenteric artery stenting versus surgical revascularization in chronic mesenteric ischemia". Int Angiol. 28 (2): 132–7. PMID 19367243.
  6. Block TA, Acosta S, Björck M (2010). "Endovascular and open surgery for acute occlusion of the superior mesenteric artery". J Vasc Surg. 52 (4): 959–66. doi:10.1016/j.jvs.2010.05.084. PMID 20620006.
  7. 7.0 7.1 Sarac TP, Altinel O, Kashyap V, Bena J, Lyden S, Sruvastava S; et al. (2008). "Endovascular treatment of stenotic and occluded visceral arteries for chronic mesenteric ischemia". J Vasc Surg. 47 (3): 485–491. doi:10.1016/j.jvs.2007.11.046. PMID 18295100.
  8. Luo QZ, Lin L, Gong Z, Mei B, Xu YJ, Huo Z; et al. (2011). "Positive association of major histocompatibility complex class I chain-related gene A polymorphism with leukemia susceptibility in the people of Han nationality of Southern China". Tissue Antigens. 78 (3): 178–84. doi:10.1111/j.1399-0039.2011.01748.x. PMID 21810082.
  9. Lee RW, Bakken AM, Palchik E, Saad WE, Davies MG (2008). "Long-term outcomes of endoluminal therapy for chronic atherosclerotic occlusive mesenteric disease". Ann Vasc Surg. 22 (4): 541–6. doi:10.1016/j.avsg.2007.09.019. PMID 18620112.